Vossen M G, Pferschy S, Milacek C, Haidinger M, Karolyi Mario, Vass Zoltan, Burgmann Heinz, Maier-Salamon Alexandra, Wicha S G, Jäger W, Zeitlinger M, Stimpfl T, Wittek T, Thalhammer F
Clinical Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Department of Internal and Emergency Medicine, Bürgerspital Solothurn, Solothurn, Switzerland.
Front Pharmacol. 2021 Jun 24;12:702455. doi: 10.3389/fphar.2021.702455. eCollection 2021.
Elimination of a drug during renal replacement therapy is not only dependent on flow rates, molecular size and protein binding, but is often influenced by difficult to predict drug membrane interactions. models allow for extensive profiling of drug clearance using a wide array of hemofilters and flow rates. We present a bovine blood based pharmacokinetic model for intermittent renal replacement therapy. Four different drugs were analyzed: gentamicin, doripenem, vancomicin and teicoplanin. The investigated drug was added to a bovine blood reservoir connected to a hemodialysis circuit. In total seven hemofilter models were analyzed using commonly employed flow rates. Pre-filter, post-filter and dialysate samples were drawn, plasmaseparated and analyzed using turbidimetric assays or HPLC. Protein binding of doripenem and vancomycin was measured in bovine plasma and compared to previously published values for human plasma. Clearance values were heavily impacted by choice of membrane material and surface as well as by dialysis parameters such as blood flow rate. Gentamicin clearance ranged from a minimum of 90.12 ml/min in a Baxter CAHP-170 diacetate hemofilter up to a maximum of 187.90 ml/min in a Fresenius medical company Fx80 polysulfone model (blood flow rate 400 ml/min, dialysate flow rate 800 ml/min). Clearance of Gentamicin vs Vancomicin over the F80s hemofilter model using the same flow rates was 137.62 mL vs 103.25 ml/min. Doripenem clearance with the Fx80 was 141.25 ml/min. Clearance values corresponded very well to previously published data from clinical pharmacokinetic trials. In conjunction with in silico pharmacometric models. This model will allow precise dosing recommendations without the need of large scale clinical trials.
肾脏替代治疗期间药物的清除不仅取决于流速、分子大小和蛋白结合情况,还常常受到难以预测的药物与膜相互作用的影响。模型能够使用多种血液滤过器和流速对药物清除情况进行广泛分析。我们提出了一种基于牛血的间歇性肾脏替代治疗药代动力学模型。分析了四种不同的药物:庆大霉素、多利培南、万古霉素和替考拉宁。将研究的药物添加到连接到血液透析回路的牛血储备器中。总共使用常用流速分析了七种血液滤过器模型。采集滤器前、滤器后和透析液样本,分离血浆并使用比浊法或高效液相色谱法进行分析。在牛血浆中测量了多利培南和万古霉素的蛋白结合情况,并与先前发表的人血浆值进行了比较。清除值受到膜材料和表面的选择以及诸如血流速率等透析参数的严重影响。庆大霉素清除率范围从百特CAHP - 170双醋酸盐血液滤过器中的最小值90.12毫升/分钟到费森尤斯医疗公司Fx80聚砜模型中的最大值187.90毫升/分钟(血流速率400毫升/分钟,透析液流速800毫升/分钟)。在使用相同流速的F80s血液滤过器模型中,庆大霉素与万古霉素的清除率分别为137.62毫升/分钟和103.25毫升/分钟。Fx80对多利培南的清除率为141.25毫升/分钟。清除值与先前发表的临床药代动力学试验数据非常吻合。结合计算机药代动力学模型,该模型将无需大规模临床试验即可给出精确的给药建议。